REMS Meeting For Opioids Shows Key Role Of Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA expects to use the two-day open meeting to delve deeper into technical issues of IT and distribution that will inform further risk mitigation programs in other drug classes.